Tag
Five-year data from KEYNOTE-826 confirm pembrolizumab combined with chemotherapy as a durable, first-line treatment improving survival in persistent, recurrent, or metastatic cervical cancer without new safety concerns.
A phase 2 trial shows bicistronic CD19/CD22 CAR T-cell therapy yields high remission rates with durable event-free survival in pediatric relapsed/refractory B-ALL, reducing antigen-negative relapse risks and improving outcomes.
Mezigdomide targets IKZF1/IKZF3 to reverse T-cell exhaustion, enhancing cytokine production and improving T-cell engager efficacy in multiple myeloma, a breakthrough in overcoming immunotherapy resistance.
This study demonstrates that T cells engineered with a dual HLA-restricted TCR against cathepsin G effectively and safely eradicate AML cells, offering a promising immunotherapy for a broad AML patient population.
This article reviews the development of high-avidity cathepsin-G-specific CAR T cells engineered with enhanced functional features to selectively target acute myeloid leukemia without hematopoietic toxicity, highlighting their preclinical e
Distinct gut microbial profiles but shared metabolomic markers, especially fecal acetate, predict response and survival with combination immunotherapy in metabolic dysfunction-associated and viral hepatitis-related hepatocellular carcinoma.
PCK1 deficiency in hepatocytes drives metabolic reprogramming that fosters MASH-HCC progression by inducing CD8+ T cell dysfunction through 12-HETE-p38 signaling, highlighting a metabolic immunotherapy target to enhance anti-PD-1 efficacy.
Baricitinib treatment in recent-onset type 1 diabetes preserves β-cell function during therapy. However, this effect diminishes within a year after stopping treatment, highlighting the need for sustained immunotherapy for lasting benefit.
A case series assessing the safety and efficacy of low-dose blinatumomab in 15 patients with multidrug-resistant rheumatoid arthritis showed synovial B-cell depletion, reduced disease activity, and improved response to previously ineffectiv
The addition of perioperative pembrolizumab to standard care improves event-free survival in locally advanced head and neck squamous cell carcinoma, with cost-effectiveness dependent on PD-L1 combined positive score.
The UK NCRI phase II trial demonstrates pembrolizumab with localized radiotherapy yields meaningful response rates and durable control in relapsed/refractory advanced cutaneous T-cell lymphoma, marking an important step in improving outcome
Anti-PD-1 therapy has transformed classical Hodgkin lymphoma management, demonstrating safety, feasibility, and durable efficacy across treatment settings—from relapsed/refractory disease to frontline therapy.
This article reviews the development and preclinical evaluation of C9-66 CAR-T cell therapy targeting oncofetal chondroitin sulfate in pancreatic cancer, highlighting metabolic and microenvironmental optimizations that improve efficacy and
Two immunologically distinct, age-independent subtypes of new-onset type 1 diabetes demonstrate differing progression rates and therapeutic responses, offering a path toward tailored immunotherapies.
The Phase 2 TREASURE trial investigated the safety and efficacy of adding consolidative thoracic radiotherapy to atezolizumab maintenance in extensive-stage small cell lung cancer, revealing increased toxicity without survival benefit, unde
This review synthesizes recent phase I trial data on CD7 CAR-T therapies in relapsed/refractory AML, highlighting promising safety, high response rates, challenges with antigen loss relapse, and avenues for future research.
A four-year post hoc analysis of the TOPAZ-1 trial confirms that durvalumab combined with gemcitabine and cisplatin offers a long-term survival benefit with manageable safety as first-line treatment for advanced biliary tract cancer.
This article reviews evolving therapeutic sequences in advanced hepatocellular carcinoma, highlighting the integration of immune-based combinations, tyrosine kinase inhibitors, liver function preservation, and the emerging multidimensional
NEK9 upregulation in hepatocellular carcinoma promotes immune evasion by enhancing PD-L1 expression and recruiting suppressive myeloid cells. Novel NEK9 inhibitors synergize with PD-L1 blockade, remodeling the tumor microenvironment and imp
MSI-H/dMMR gastroesophageal adenocarcinoma showed high response rates to immune checkpoint inhibitors, including durable complete responses in locoregional disease that may support carefully selected nonoperative management.
